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Background Although generic anti-retroviral drugs are in common use through-
out the developing world, studies comparing their clinical effective-
ness with that of proprietary formulations are lacking.
Methods We analysed observational data from a large cohort of adults
on anti-retroviral therapy (ART) to assess potential differences
between generic and proprietary zidovudine (ZDV) formulations
in post-90-day mortality, ‘programme failure’ (a composite of
death, follow-up losses and withdrawals) and other clinical
outcomes. We accounted for drug exposure in three ways: an ‘initial
dispensation’ approach that categorized patients according to the
first prescription; ‘time-varying’ approach that attributed an
outcome to the formulation taken at the time of event; and ‘pre-
dominant exposure’ approach that considered only those with475%
exposure to either brand or generic ZDV. Proprietary formulations
were used as the reference group in all adjusted Cox proportional
hazard regressions.
Results Among 14736 patients eligible for analysis, 7277 (49%) initiated a
generic formulation of ZDV and 7459 (51%) initiated a proprietary
formulation. When categorized according to initial dispensation, no
difference in post-90-day mortality was observed between the two
groups [adjusted hazard ratio (AHR): 0.93, 95% confidence interval
(CI): 0.77–1.12]. Similar findings were noted when drug formula-
tion was treated as a time-varying exposure (AHR: 1.15, 95% CI:
0.89–1.48) when analysis was limited to those with a predominant
exposure to one formulation or the other (AHR: 0.59, 95% CI:
0.24–1.49). Results were consistent across all approaches when
programme failure was considered as an outcome. No longitudinal
differences were detected between formulations for CD4 response,
weight change and haemoglobin concentration. Generic ZDV
formulations were associated with slight decreases in single-drug
substitution.
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448Conclusions In this large programmatic cohort of adults starting ZDV-based
first-line therapy, clinical outcomes appeared similar among
patients on generic or proprietary formulations. These findings
support continued use of generic anti-retroviral drug formulations
in resource-constrained settings.
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Introduction
The worldwide majority of patients receiving anti-
retroviral therapy (ART) now live in sub-Saharan
Africa.
1 Among the most important steps in achieving
this historic benchmark has been the substantial price
reduction in anti-retroviral drugs. Once deemed too ex-
pensive for widespread use in poor nations, anti-
retroviral drugs have become increasingly affordable
in recent years, owing to both the price negotiations
with proprietary manufacturers and the emergence
of a wide variety of new generic formulations.
2–6
The World Health Organization (WHO) recommends
a limited formulary of triple-drug anti-retroviral
regimens as first-line therapy for treatment of adults
and adolescents in most developing world settings.
7
The WHO also recommends that all anti-retroviral
drugs undergo continuous quality assessment, and
has established a ‘prequalification programme’ to
assist host governments in their drug procurement.
8
The US government, which is the largest single donor
to the global AIDS mitigation effort,
9 does not
recognize the WHO pre-qualification process and
instead requires approval by the US Food and Drug
Administration (FDA) for any anti-retroviral drugs
purchased with American funds.
10 To date, 133 generic
formulations have been approved in this manner,
dating back to December 2004.
11 Despite these rigorous
approval processes, questions persist regarding the
ongoing quality and bioequivalence of many generic
formulations,
12 particularly since continuing ‘post-
approval’ evaluations have proven difficult to enforce.
The Zambian government’s ART programme in the
Lusaka Urban District is a well-documented cohort
with large patient numbers, careful prospective data
collection and commingling of both proprietary and
generic formulations.
13,14 We sought to compare the
field effectiveness of proprietary and generic first-line
ART regimens in a field setting. To ensure maximum
comparability(seerationalebelow),welimitedourana-
lysis to patients initiating a ZDV-containing regimen.
Methods
Clinical care
Details of the clinical care procedures followed in the
Lusaka Urban District have been described in detail
elsewhere.
13–16 We emphasize here a few aspects that
require further explication for the current report.
During the study period, ART eligibility was deter-
mined according to the Zambian national guidelines,
which closely followed recommendations by the
WHO: CD4
þ cell count <200/ml and WHO clinical
stage 4, or CD4
þ cell count <350/ml and WHO clinical
stage 3.
17 First-line anti-retroviral prescriptions
comprised three drugs. These were either ZDV or
stavudine (d4T), plus lamivudine (3TC) plus either
nevirapine (NVP) or efavirenz (EFV). We started
ZDV- or d4T-based regimens based upon drug avail-
ability, but typically did not initiate ZDV in patients
whose haemoglobin was <10g/dl.
The initial follow-up schedule for those starting ART
included six visits during the first 3 months, with spe-
cial focus on adherence and detecting adverse events.
For individuals receiving a ZDV-containing regimen,
haemoglobin levels were monitored at post-initiation
weeks 2, 4 and 8. CD4
þ cell counts were performed
every 6 months. In our setting, virological monitoring
isnotroutinelyused;however,viralloadtestingisavail-
able to clinicians when discordant immunological and
clinical evaluations require adjudication.
18 Contact tra-
cing by community health workers is scheduled for all
ART patients when they remain delinquent for clinical
appointments after 10 days.
19 Patient death was ascer-
tained by reports from clinical facilities, home-based
care organizations and follow-up visits by community
health workers.
Anti-retroviral drugs were dispensed monthly. In
each of the 18 Lusaka facilities, clinical and pharmacy
encounters occurred in physically separate areas.
Clinicians wrote prescriptions, but did not indicate
whether they were to be filled with generic or propri-
etary drugs. Prescriptions were filled on-site by
pharmacy technicians. Efforts were made to continue
a given patient on the same regimen and formulation
at each subsequent visit. However, switching between
proprietary and generic formulations was common,
and depended upon what agents were available
in the pharmacy when the patient presented.
Programme data were collected on standardized care
forms and transcribed on-site into an electronic
medical record and patient tracking system adopted
by the Zambian Ministry of Health.
20
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We included all ART-naı ¨ve adult patients (416 years
of age) initiating care at public sector facilities in the
Lusaka Urban District. As already noted, patients
switched commonly between generic and proprietary
formulations for pharmacy stock (and not clinical)
reasons. Similar amounts of proprietary and generic
ZDV were available through most of the evaluation
period, although generic dispensation predominated
towards the end of our observation period. This facili-
tates what we believe to be a valid comparison of
ZDV-related outcomes among patients prescribed pro-
prietary versus generic formulations. In contrast, there
was much less proprietary d4T available (<10% of all
d4T prescriptions) and the dispensation of proprietary
d4T was not random, as it was not available in
a proprietary fixed-dose combination. For this
reason, we have limited this analysis to patients initi-
ating a ZDV-containing regimen. We included in this
analysis adults initiating ART between programme
inception and 1 July 2007, when the Zambian
Ministry of Health changed recommended first-line
ART to tenofovir-containing regimens.
21 Observation
continued until the data freeze date of 30 November
2010.
Outcomes and analytical methods
Although early mortality (i.e. deaths within 90 days of
starting therapy) is high in our setting,
13,14 the indi-
vidual components of a drug regimen are unlikely to
be related to early death. For this reason, we focused
on post-90-day mortality as our primary outcome
measure. Consistent with previous work,
21,22 we also
examined the association between ZDV formulation
(i.e. proprietary or generic) and ‘programme failure’,
a composite outcome that considered death, follow-up
losses and formal withdrawals from the ART clinic.
Patients receiving ART who were 460 days late for
a pharmacy or clinical appointment (and who were
not known to have died or formally withdrawn from
the programme) were considered lost to follow-up.
23
As with past analyses,
22 we considered three analyt-
ical approaches. In the ‘initial dispensation analysis’, a
given patient’s drug exposure was determined by his
or her second month’s dispensation. (We excluded
from the analysis any patient who contributed 30
person-days because prescriptions made during the
first month of therapy, when the NVP dose is being
escalated,
24 typically commingle proprietary and
generic formulations in the same month, making clas-
sification impossible.) Under the initial dispensation
assumption, a patient who received an initial generic
dispensation would be categorized as exposed exclu-
sively to generic drug, even if he or she switched to a
proprietary formulation at some point during therapy.
In the ‘time-varying exposure’ analysis, a given
patient’s drug exposure(s) are allowed to vary
over time in the Cox model. Thus, an individual
patient who switches formulations may contribute
person-time to both categories of exposure in the pro-
portional hazards regression. Finally, in an attempt to
further understand the effects of switching between
formulations, we characterized patients’ ‘predominant
drug exposure’ during their first year on therapy as
mostly (i.e. 575% of dispensations) generic or propri-
etary, and then examined our outcomes of interest in
the 365 days that followed. Those who did not meet
this dispensation threshold—i.e. those with 75% of
either generic or proprietary ZDV formulations—
were excluded from this exploratory analysis, as
were individuals contributing <12 months of
follow-up time.
Over the observation period, anti-retroviral drugs
were purchased from manufacturers by the Zambian
government and donors such as the US President’s
Emergency Plan for AIDS Relief (PEPFAR).
Although we could reliably classify formulations as
generic or proprietary, we were unable to further
categorize regimens by their different manufacturer
or, for generic formulations, their qualification
status from WHO or FDA. Regardless of the manu-
facturer, ZDV was most commonly dispensed as a
two-drug co-formulation with 3TC. Occasionally
patients received generic fixed-dose combinations of
ZDVþ3TCþNVP, but this was far less frequent. ZDV
was rarely given as a single pill in combination with
ART. We categorized regimens based only on the ZDV
formulation, even though the dispensation of other
regimen components (e.g. NVP and EFV) could vary
between proprietary and generic formulations as well.
When assessing baseline characteristics among
analysis groups, we compared continuous variables
with a Wilcoxon rank sum test and compared
dichotomous and categorical variables with the
Pearson 
2-test statistic. In the initial dispensation
analysis and the predominant drug exposure analysis,
we fitted Kaplan–Meier curves to examine survival
functions and used the log-rank test to examine stat-
istical difference among groups. For all three analyt-
ical approaches, we estimated hazard ratios (HRs) for
mortality using Cox proportional hazards regression
and tested the proportional hazards assumption for
potential interaction between each variable and time
in a given model using the likelihood ratio test.
We adjusted for potential confounders shown to be
associated with our outcomes of interest in the previ-
ous work.
13 Many of these characteristics were
routinely collected at baseline (i.e. within 1 month
of ART initiation). We assessed adherence using the
medication possession ratio (MPR), a metric that has
been linked to patient survival, immunological recov-
ery and virological outcomes in our setting.
18,25 MPR
is calculated by dividing the cumulative number of
days a patient is late for pharmacy visits by the
total number of days on therapy, and then subtracting
this percentage from 100%. In the initial dispensation
(first 90 days) and the predominant exposure (first
365 days) analyses, MPR was measured over an initial
450 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYwindow period. Adherence was not considered in the
time-varying analysis. We performed all reported
proportional hazard regressions with a stratification
by calendar year—to account for the possibility that
care delivery may have improved (or declined) over
time. Patients switching to a d4T-containing regimen
and/or to a protease inhibitor-based regimen were
censored at the time of regimen modification. When
drug information was missing for a specific dispensa-
tion, it was carried over from the last patient
interaction.
We studied other clinical outcomes according to an
individual’s initial dispensation. As a surrogate for
ZDV toxicity, we calculated the rate of single-drug
substitution—from ZDV to d4T—for patients allocated
to the proprietary and generic categories, and
described these trends using adjusted time-to-event
analyses. The prevalence of clinically significant anae-
mia in our setting (i.e. haemoglobin <8.0g/dl) at
90 days was also measured among patients initiating
proprietary and generic ZDV formulations. Finally, we
compared the median longitudinal change in CD4
þ
cell count, haemoglobin levels and weight for the
two comparison arms. We used SAS version 9.1.3
(SAS Institute, Cary, NC, USA) for all analyses.
This reporting of programmatic data was approved
by the Institutional Review Boards of the University
of Zambia (Lusaka, Zambia) and the University of
Alabama at Birmingham (Birmingham, AL, USA).
Results
Between 26 April 2004 and 1 July 2007, we enrolled
33724 HIV-1 seropositive treatment-naı ¨ve adults
(416 years of age) for entry into the Lusaka District
HIV Care and Treatment Program (Figure 1). Of
these, 929 died and 168 were lost to follow-up prior
Figure 1 Cohort profile of patients initiating ART between May 2004 and July 2007 (Lusaka, Zambia)
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were able to reliably characterize the initial drug
exposure as either generic or proprietary). An add-
itional 15997 patients initiated a non-ZDV-containing
regimen and 9 initiated ZDV, but available data did
not allow classification as generic or proprietary drug
exposure. The remaining 16621 patients achieved at
least 30 days of follow-up on a ZDV-containing
first-line regimen. Between 31 and 90 days on ther-
apy, an additional 358 patients died, 536 were lost to
follow-up and 991 switched to a non-ZDV-containing
regimen. Thus, 14736 patients were available for the
post-90-day (primary) analysis, contributing a median
of 1373 days [interquartile range (IQR): 592–1798]
of observation time (Figure 1). Demographic and
medical characteristics, categorized according to a
patient’s initial ZDV formulation, are shown in
Table 1.
Among 14736 patients in the analysis dataset,
13642 (93%) started a regimen of ZDVþ3TCþNVP
and 1094 (7%) started a regimen of ZDVþ3TCþEFV.
A total of 7459 (51%) patients initiated a proprietary
ZDV formulation (median follow-up: 1519 days; IQR:
798–1889), whereas 7277 (49%) initiated a generic
Table 1 Baseline characteristics of adults initiating generic or proprietary ZDV-containing anti-retroviral regimens between
May 2004 and July 2007 (Lusaka, Zambia)
Patients initiating a
proprietary formulation
(N¼7459)
Patients initiating a
generic formulation
(N¼7277)
N Value N Value P value
Age 7459 35 (30, 41) 7277 35 (30, 41) 0.29
16–29 years 1749 23.4% 1681 23.1% 0.96
30–34 years 1866 25.0% 1819 25.0%
35–39 years 1573 21.1% 1545 21.2%
540 years 2271 30.4% 2232 30.7%
Male 3267 43.8% 3265 44.9% 0.19
BMI (kg/m
2) 6536 20.5 (18.7, 22.8) 6576 20.3 (18.4, 22.6) <0.01
516 6239 95.5% 6267 95.3% 0.67
<16 297 4.5% 309 4.7%
Baseline CD4
þ cell count (cells/mm
3) 7279 139 (78, 202) 7050 139 (76, 200) 0.46
5200 1875 25.8% 1782 25.3% 0.32
50–199 4357 59.9% 4192 59.5%
<50 1047 14.4% 1076 15.3%
Baseline haemoglobin concentration 6494 11.8 (10.8, 13.0) 6433 11.8 (10.8, 12.9) 0.32
510.0 5289 91.6% 5180 90.2% 0.03
8.0–9.9 441 7.6% 498 8.7%
<8.0 46 0.8% 62 1.1%
Active tuberculosis at enrolment 988 13.2% 942 12.9%
WHO clinical stage
Stage I or II 2692 36.3% 2519 34.7% 0.11
Stage III 4136 55.7% 4150 57.2%
Stage IV 597 8.0% 589 8.1%
Adherence over first 90 days (%) 7459 100 (92, 100) 7277 100 (92, 100) 0.50
95–100 974 13.1% 936 12.9% 0.96
80–94 1536 20.6% 1468 20.2%
<80 984 13.2% 957 13.2%
Observation time, days, median (IQR) 7459 1519 (798, 1889) 7277 1329 (758, 1791) <0.01
Number of switches between
formulations, median (IQR)
7459 3 (1, 5) 7277 2 (0, 5) <0.01
Time to first switch, days, median (IQR) 6327 122 (73, 207) 4833 88 (58, 143) <0.01
452 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYformulation (median follow-up: 1329 days; IQR: 758–
1791). Patients were prescribed a total of 119295
monthly prescriptions for proprietary ZDV and
321349 prescriptions for generic ZDV (Figure 2). The
majority of patients (11160, 76%) were switched from
a proprietary formulation to a generic formulation or
vice versa by their pharmacist; 6327 switched from
brand to generic (median time to first switch: 122
days, IQR: 73–207), whereas 4833 switched from gen-
eric to brand (median time to first switch: 88 days,
IQR: 58–143). A Kaplan–Meier analysis showing time
to first switch is shown in Figure 3a.
Survival
When we considered those who remained active and
in care for at least 90 days, 983 patients died over
49136 patient-years of follow-up, a rate of 2.0 per
100 patient-years [95% confidence interval (CI):
1.9–2.1]. The hazard of death associated with generic
formulations did not appear different from that of
proprietary ZDV across the varying statistical
approaches: initial dispensation (AHR: 0.93, 95% CI:
0.77–1.12), time-varying (AHR: 1.15, 95% CI:
0.89–1.48) or predominant exposure (AHR: 0.59,
95% CI: 0.24–1.49). The baseline CD4
þ count and
the WHO stage were consistently associated with
the mortality outcome, whereas the association
between death and other covariates [e.g. sex, body
mass index (BMI) and adherence] varied with
approach (Table 2).
Programme failure
When we considered post-90-day programme failure
as our outcome, 6995 patients met the definition for
this analysis endpoint over the observation period
(rate: 13.3 per 100 patient-years, 95% CI: 13.0–13.6).
We were unable to detect any differences between
generic and proprietary ZDV across our three statis-
tical approaches: initial dispensation (AHR: 1.00, 95%
CI: 0.93–1.07), time-varying (AHR: 0.91, 95% CI:
0.82–1.00) or predominant exposure (AHR: 0.85,
95% CI: 0.59–1.23). The association between
programme failure and other covariates of interest
resembled that of our mortality analyses (Table 3).
Other outcomes
The rate of single-drug substitution, a surrogate
marker for ZDV drug toxicity, was 10.5 (95% CI:
10.2–10.8) in our overall cohort (Figure 3b). In the
adjusted Cox regression models, generic ZDV had
slightly lower hazard of substitution when compared
with proprietary formulations (AHR: 0.91, 95% CI:
0.84–0.99). The prevalence of diagnosed severe
anaemia at 90 days likewise did not differ. Of the
2937 patients, 107 (4.7%) patients initiating a generic
formulation and in whom haemoglobin information
was available had at least one haemoglobin measure-
ment <8.0g/dl compared with 81 of 1938 (4.2%) pa-
tients initiating a proprietary formulation (P¼0.41).
Patients initiating proprietary and generic formula-
tions had similar rises in their median CD4
þ counts,
haemoglobin concentrations and weight over the
observation period (Figure 4a–c).
Discussion
In this large analysis of programmatic data from a
public sector ART programme in Lusaka, Zambia,
patients who were dispensed generic drugs had simi-
lar outcomes to those who were dispensed proprietary
drugs. Specifically, we were unable to detect any
differences in mortality, programme failure, CD4
þ
lymphocyte response, haemoglobin response or
weight gain that could be attributed to generic drug
exposure.
The costs between proprietary and generic drugs
continue to differ greatly. The per patient cost for
ZDV-3TC co-formulations, an example central to the
current analysis, is estimated at $231/year for branded
drugs compared with $101–123/year for generic
formulations.
26 It is therefore not surprising that, as
the volume of procured anti-retroviral drugs has
increased dramatically worldwide, the proportion of
generic formulations purchased has also skyrocketed.
In a survey of 16 countries, Holmes et al. found that
the proportion of generic drugs purchased through
PEPFAR gradually increased from 14.8% in 2005 to
89.3% in 2008. (Programmes in Zambia followed
this general trend, with notable increases in generic
drug as a proportion of overall procurement: 42.8% in
2005, 56.5% in 2006, 91.3% in 2007 and 93.7% in
2008.) The total cost savings associated with this
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Figure 2 Dispensation of generic and proprietary formula-
tions of ZDV from May 2004 to November 2010 (Lusaka,
Zambia)
GENERIC ANTI-RETROVIRAL THERAPY IN ZAMBIA 453shift—from proprietary to generic formulations—was
estimated at $323 million over the 4-year period.
10
The effectiveness of generic anti-retroviral formula-
tions thus remains an important scientific question,
one with obvious public health implications.
Pharmacological analyses of generic anti-retroviral
drugs have generally confirmed bioequivalence when
compared with their proprietary counterparts.
27–33
In cohort studies, generic formulations have also
been associated with consistently favourable
treatment responses.
34–45 Laurent et al., for example,
demonstrated a high rate of virological suppression
(80%) and favourable CD4
þ treatment responses
(median þ83 cells/ml) among 60 patients on generic
fixed-dose combination drugs at 24 weeks. Although
the proportion with virological suppression decreased
in the second year of therapy, overall outcomes ap-
peared comparable with other treatment cohorts in
the region.
35 Idigbe et al.
36 demonstrated encouraging
virological responses at 24 weeks and immunological
responses at 48 weeks among 50 Nigerian adults
on ART. Pujari et al.
37 reported similar outcomes
Figure 3 Kaplan–Meier analysis showing time to first switch between proprietary and generic formulations (a) and time to
single-drug substitution from ZDV to other anti-retroviral agent, a surrogate marker for drug toxicity (b) among patients
enrolled from May 2004 to July 2007 (Lusaka, Zambia)
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anti-retroviral formulations were used exclusively for
treatment. No virological data were collected, but
therapy resulted in significant and sustained CD4
response up to 24 months. In a cohort of 6861
patients across 21 Medecins Sans Frontieres sites,
Calmy et al.
38 reported similarly favourable health
responses to fixed-dose combinations from non-
proprietary manufacturers. To our knowledge, how-
ever, no study has directly compared clinical
outcomes associated with generic and proprietary
formulations.
A strength of this study lies in its large sample size.
Our population of almost 15000 patients allowed for
powerful comparisons of the generic drug formula-
tions vs their brand name counterparts, and could
be expected to detect differences in their effectiveness.
This is complemented by the specifics of drug pre-
scription and dispensation in the Lusaka programme.
There is no provision for the clinicians caring for
Table 2 Factors associated with post-90-day mortality among adults initiating generic or proprietary ZDV-containing
anti-retroviral regimens between May 2004 and July 2007 (Lusaka, Zambia)
Initial dispensation Time-varying Predominant exposure
Adjusted hazard ratio (95% CI) Adjusted hazard ratio (95% CI) Adjusted hazard ratio (95% CI)
Drug formulation dispensed
Proprietary 1.0 1.0 1.0
Generic 0.93 (0.77–1.12) 1.15 (0.89–1.48) 0.59 (0.24–1.49)
Age (years)
16–29 1.0 1.0 1.0
30–34 0.89 (0.69–1.13) 0.95 (0.71–1.27) 0.76 (0.43–1.35)
35–39 1.07 (0.84–1.37) 1.13 (0.85–1.51) 1.29 (0.76–2.19)
540 1.22 (0.97–1.53) 1.34 (1.02–1.74) 1.47 (0.90–2.41)
Sex
Female 1.0 1.0 1.0
Male 1.46 (1.24–1.72) 1.38 (1.14–1.68) 0.89 (0.62–1.28)
BMI (kg/m
2)
516 1.0 1.0 1.0
<16 2.19 (1.67–2.86) 2.22 (1.64–3.01) 1.01 (0.44–2.32)
Baseline CD4
þ cell count (cells/mm
3)
5200 1.0 1.0 1.0
50–199 1.15 (0.93–1.42) 1.22 (0.96–1.56) 1.20 (0.77–1.87)
<50 1.62 (1.27–2.07) 1.70 (1.28–2.25) 1.76 (1.03–3.01)
Baseline haemoglobin concentration
510.0 1.0 1.0 1.0
8.0–9.9 1.46 (1.13–1.90) 1.66 (1.25–2.21) 1.23 (0.68–2.21)
<8.0 1.35 (0.63–2.92) 0.97 (0.31–3.02) 2.00 (0.49–8.07)
Tuberculosis at enrolment
No 1.0 1.0 1.0
Yes 0.97 (0.78–1.22) 1.13 (0.89–1.44) 0.86 (0.52–1.44)
WHO clinical stage
Stage I or II 1.0 1.0 1.0
Stage III 1.48 (1.21–1.81) 1.58 (1.24–2.01) 1.61 (1.05–2.46)
Stage IV 2.43 (1.84–3.23) 2.73 (1.97–3.79) 2.69 (1.48–4.88)
Adherence (%)
95–100 1.0 N/A 1.0
80–94 0.70 (0.56–0.87) N/A 1.05 (0.70–1.59)
<80 1.42 (1.14–1.76) N/A 2.43 (1.48–3.98)
GENERIC ANTI-RETROVIRAL THERAPY IN ZAMBIA 455patients to indicate whether a given prescription is to
be filled with a particular formulation. Dispensation
occurs in separate pharmacy areas and is driven by
the availability of drugs, with an effort made to main-
tain a given patient on the same formulation from
month to month. This permitted a unique natural ex-
periment; whereas this was not a randomized trial, it
was close to one, as initial exposure to proprietary
versus generic formulations was essentially random.
Our data included a large number of patients
who switched between proprietary and generic
formulations. Although we maintain that this switch-
ing was essentially random early in the course of ob-
servation, procurement of generic ZDV formulations
(vs brand name ones) increased dramatically after
2007 (Figure 2). This phenomenon might be expected
to bias the results of our initial dispensation analysis
towards the null hypothesis, since such crossover
would make the two exposure groups more similar.
To address this issue, we conducted two complemen-
tary statistical analyses, using (i) a time-varying
approach that attributed patient outcomes to the
Table 3 Factors associated with programme failure among adults initiating generic or proprietary ZDV-containing
anti-retroviral regimens between May 2004 and July 2007 (Lusaka, Zambia)
Initial dispensation Time-varying Predominant exposure
Adjusted hazard ratio (95% CI) Adjusted hazard ratio (95% CI) Adjusted hazard ratio (95% CI)
Drug formulation dispensed
Proprietary 1.0 1.0 1.0
Generic 1.00 (0.93–1.07) 0.91 (0.82–1.00) 0.85 (0.59–1.23)
Age (years)
16–29 1.0 1.0 1.0
30–34 0.78 (0.72–0.84) 0.77 (0.70–0.84) 0.64 (0.53–0.78)
35–39 0.69 (0.63–0.75) 0.69 (0.63–0.76) 0.71 (0.58–0.86)
540 0.66 (0.61–0.71) 0.64 (0.59–0.70) 0.69 (0.58–0.83)
Sex
Female 1.0 1.0 1.0
Male 1.31 (1.24–1.40) 1.29 (1.20–1.38) 1.22 (1.06–1.41)
BMI (kg/m
2)
516 1.0 1.0 1.0
<16 1.47 (1.30–1.67) 1.49 (1.29–1.71) 1.18 (0.86–1.63)
Baseline CD4
þ cell count (cells/mm
3)
5200 1.0 1.0 1.0
50–199 0.99 (0.92–1.06) 0.96 (0.89–1.04) 0.88 (0.75–1.03)
<50 1.01 (0.92–1.11) 0.96 (0.86–1.07) 0.91 (0.72–1.14)
Baseline haemoglobin concentration
510.0 1.0 1.0 1.0
8.0–9.9 1.22 (1.10–1.36) 1.30 (1.15–1.47) 1.20 (0.93–1.55)
<8.0 1.40 (1.01–1.93) 1.58 (1.11–2.23) 1.64 (0.89–3.03)
Tuberculosis at enrolment
No 1.0 1.0 1.0
Yes 0.90 (0.82–0.99) 0.92 (0.83–1.01) 1.01 (0.82–1.24)
WHO clinical stage
Stage I or II 1.0 1.0 1.0
Stage III 1.14 (1.07–1.22) 1.12 (1.04–1.20) 1.07 (0.91–1.25)
Stage IV 1.37 (1.23–1.54) 1.31 (1.16–1.49) 1.17 (0.90–1.54)
Adherence (%)
95–100 1.0 N/A 1.0
80–94 0.95 (0.87–1.02) N/A 1.42 (1.21–1.67)
<80 1.43 (1.31–1.56) N/A 2.86 (2.35–3.48)
456 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYZDV formulation prescribed at the time of the event,
and (ii) a predominant exposure categorization that
limited comparisons to patients with exclusive or near
exclusive exposures of either proprietary or generic
ZDV. The consistency of findings across these two
analyses was reassuring and suggests that, on a
public health scale, proprietary and generic formula-
tions may not differ with respect to clinical outcomes.
We note several limitations to our analysis. First,
although the treatment programme has been ongoing
since April 2004, subtle differences between the
studied formulations could take longer periods to
manifest. Virological monitoring could lead to earlier
detection of treatment failure, but such testing is not
routinely available in our setting. Secondly, like many
cohorts in the region,
46 a significant proportion of
deaths may have been misclassified as follow-up
losses. Such miscategorization would likely be
random and not favour one allocation arm over the
other; however, to confirm this assumption, we
employed a composite outcome (i.e. programme
failure) that considered those lost to follow-up as
meeting a study endpoint. We were reassured to
find minimal difference between our two outcomes
of interest across the range of analytical approaches.
Thirdly, we categorized ART as either generic or
proprietary based solely on the ZDV formulation. For
reasons of complexity, we did not consider these same
characteristics for other components of the three-drug
combination, in particular NVP or EFV. If a difference
were to exist in the efficacy of these formulations, it
would incorrectly bias our results towards the null
hypothesis. Fourth, we were unable to further cat-
egorize generic ZDV formulations by manufacturer,
the WHO pre-qualification or the FDA approval.
Although such analyses could have provided import-
ant insight, a stratified analysis incorporating these
factors would have magnified the central methodo-
logical challenge associated with this analysis:
switching between drug formulations.
In Zambia, where an estimated 1 million adults and
children are infected with HIV—all of whom will
eventually require ART—even modest differences in
drug prices could mean the difference between uni-
versal access and more limited services. Procurement
of the cheapest effective medicines possible is critical
to the national response to AIDS. We are encouraged
to find that the use of generic formulations in this
large patient cohort was associated with very favour-
able outcomes, and outcomes that were very much
comparable to those achieved with proprietary
formulations. Like that of many neighbouring coun-
tries, Zambian government’s decision to procure and
prescribe these drugs was a sound one.
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KEY MESSAGES
  In the context of a large HIV treatment programme in Lusaka, Zambia, no detectable differences in
mortality, programme failure or other clinical outcomes were observed when generic formulations of
ZDV-based ART were compared with their proprietary counterparts.
  These findings remained consistent across three statistical approaches for categorizing patient drug
exposure.
  Our results provide reassurance to many programmes in the sub-Saharan Africa region, which—for
reasons of cost and availability—have relied heavily on generic manufacturers for their rapidly
expanding ART programmes.
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